These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 2169779)

  • 21. Tropisetron (Navoban) alone and in combination with dexamethasone in the prevention of chemotherapy-induced emesis: the Nordic experience.
    Sorbe BG
    Semin Oncol; 1994 Oct; 21(5 Suppl 9):20-6. PubMed ID: 9113123
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High versus low dose granisetron, a selective 5HT3 antagonist, for the prevention of chemotherapy-induced nausea and vomiting.
    Falkson HC; Falkson CI; Falkson G
    Invest New Drugs; 1990 Nov; 8(4):407-9. PubMed ID: 1964678
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of tropisetron and granisetron in the control of nausea and vomiting in children receiving combined cancer chemotherapy.
    Aksoylar S; Akman SA; Ozgenç F; Kansoy S
    Pediatr Hematol Oncol; 2001 Sep; 18(6):397-406. PubMed ID: 11554235
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of prophylactic intravenous granisetron in postoperative emesis in adults.
    Hanaoka K; Toyooka H; Kugimiya T; Ohashi Y;
    J Anesth; 2004; 18(3):158-65. PubMed ID: 15290412
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [BRL 43694A--a 5-hydroxytryptamine receptor blocker as an antiemetic in cytostatic therapy].
    Joss R; Rohrbach D; Buser K; Pirovino M; Karde C; Brunner K
    Schweiz Med Wochenschr; 1989 Jun; 119(23):831-4. PubMed ID: 2549616
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antiemetic efficacy of three serotonin antagonists during high-dose chemotherapy and autologous stem cell transplantation in malignant lymphoma.
    Slabý J; Trnený M; Procházka B; Klener P
    Neoplasma; 2000; 47(5):319-22. PubMed ID: 11130251
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Granisetron compared with prednisolone plus metopimazine as anti-emetic prophylaxis during multiple cycles of moderately emetogenic chemotherapy.
    Sigsgaard T; Herrstedt J; Andersen LJ; Havsteen H; Langer SW; Kjaerbøl AG; Lund H; Kjaer M; Dombernowsky P
    Br J Cancer; 1999 May; 80(3-4):412-8. PubMed ID: 10408847
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Double-blind comparative trial of oral ondansetron versus oral granisetron versus IV ondansetron in the prevention of nausea and vomiting associated with highly emetogenic preparative regimens prior to stem cell transplantation.
    Fox-Geiman MP; Fisher SG; Kiley K; Fletcher-Gonzalez D; Porter N; Stiff P
    Biol Blood Marrow Transplant; 2001; 7(11):596-603. PubMed ID: 11760147
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [A randomized cross-over comparative study of granisetron alone and combination of granisetron, methylprednisolone and droperidol as antiemetic prophilaxis in CDDP-based chemotherapy for gynecologic cancer].
    Wataba K; Sagae S; Fukunaka N; Sugimura M; Akutagawa N; Hayashi T; Yamana K; Nakamura T; Terasawa K; Mizumoto H; Kitajima Y; Kudo R
    Gan To Kagaku Ryoho; 1997 Apr; 24(6):691-7. PubMed ID: 9126306
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative crossover trial of two intravenous doses of granisetron (1 mg vs 3 mg) + dexamethasone in the prevention of acute cis-platinum-induced emesis.
    Martoni A; Piana E; Strocchi E; Angelelli B; Guaraldi M; Zamagni C; Camaggi CM; Pannuti F
    Anticancer Res; 1998; 18(4B):2799-803. PubMed ID: 9713464
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Repeated use of granisetron in patients receiving cytostatic agents.
    de Wet M; Falkson G; Rapoport BL
    Cancer; 1993 Jun; 71(12):4043-9. PubMed ID: 8389659
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of granisetron, ondansetron, and tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer: a randomized controlled trial.
    Mantovani G; Macciò A; Bianchi A; Curreli L; Ghiani M; Proto E; Santona MC
    Cancer; 1996 Mar; 77(5):941-8. PubMed ID: 8608488
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting.
    Chawla SP; Grunberg SM; Gralla RJ; Hesketh PJ; Rittenberg C; Elmer ME; Schmidt C; Taylor A; Carides AD; Evans JK; Horgan KJ
    Cancer; 2003 May; 97(9):2290-300. PubMed ID: 12712486
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.
    de Wit R; Herrstedt J; Rapoport B; Carides AD; Guoguang-Ma J; Elmer M; Schmidt C; Evans JK; Horgan KJ
    Eur J Cancer; 2004 Feb; 40(3):403-10. PubMed ID: 14746859
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A dose-finding study of granisetron, a novel antiemetic, in patients receiving cytostatic chemotherapy. The Granisetron Study Group.
    Smith IE
    J Cancer Res Clin Oncol; 1993; 119(6):350-4. PubMed ID: 8383688
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase I/II trial of granisetron: a novel 5-hydroxytryptamine antagonist for the prevention of chemotherapy-induced nausea and vomiting.
    Addelman M; Erlichman C; Fine S; Warr D; Murray C
    J Clin Oncol; 1990 Feb; 8(2):337-41. PubMed ID: 2153767
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of granisetron in the prevention of chemotherapy-induced emesis in paediatric patients.
    Lemerle J; Amaral D; Southall DP; Upward J; Murdoch RD
    Eur J Cancer; 1991; 27(9):1081-3. PubMed ID: 1659848
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Granisetron, a selective 5-HT3 receptor antagonist, for the prevention of radiation induced emesis during total body irradiation.
    Hunter AE; Prentice HG; Pothecary K; Coumar A; Collis C; Upward J; Murdoch R; Gandhi L; Hamon M; Butler M
    Bone Marrow Transplant; 1991 Jun; 7(6):439-41. PubMed ID: 1651794
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of different doses of granisetron for the prophylaxis of cisplatin-induced emesis.
    Perez EA; Navari RM; Kaplan HG; Gralla RJ; Grunberg SM; Palmer RH; Fitts D
    Support Care Cancer; 1997 Jan; 5(1):31-7. PubMed ID: 9010987
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dose finding study of granisetron in patients receiving high-dose cisplatin chemotherapy. The Granisetron Study Group.
    Riviere A
    Br J Cancer; 1994 May; 69(5):967-71. PubMed ID: 8180032
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.